medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 1

<< Back Next >>

Ann Hepatol 2009; 8 (1)

Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis

Tabibian JH, Landaverde C, Winn J, Geller SA, Nissen NN

Language: Spanish
References: 27
Page: 64-67
PDF size: 160.29 Kb.


Text Extraction

Hepatitis C poses a substantial global health burden. Three to five percent of individuals with liver cirrhosis secondary to hepatitis C will develop hepatocellular carcinoma. The development of hepatocellular carcinoma is closely associated with cirrhosis in hepatitis C infection, whereas in hepatitis B virus infection, hepatocellular carcinoma may occur in the absence of cirrhosis. Although uncommon, hepatocellular carcinoma has been reported in hepatitis C patients without cirrhosis and, in very rare cases, in the absence of active viral replication. We report the case of a 51-year-old patient with hepatitis C who developed hepatocellular carcinoma in the absence of fibrosis and after having achieved sustained virological response with combination peginterferon and ribavirin therapy seven years prior. The patient successfully underwent surgical resection, and histopathological examination of the resected tissue demonstrated a poorly-differentiated hepatocellular carcinoma in an otherwise unremarkable liver. The patient continues to do well and has no evidence of tumor recurrence 18 months post-operatively. This case raises question regarding the carcinogenesis of hepatocellular carcinoma as a sequela of chronic hepatitis C in noncirrhotic liver and moreover after achieving sustained virological response.


REFERENCES

  1. Hepatitis C Fact Sheet, Trends and Statistics (2006). Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA. http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. Cited 8 Dec 2006.

  2. WHO Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatol 1999; 6: 35-47.

  3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.

  4. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42(7): 513-215.

  5. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23; discussion 947.

  6. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 US residents. Radiology 2002; 222: 89-94.

  7. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5.

  8. Herr W, Gerken G, Poralla T, Immenschuh S, Schirmacher P, Steegmüller KW, Schwickert H, Meyer zum Büschenfelde KH. Hepatitis C virus associated primary hepatocellular carcinoma in a noncirrhotic liver. Clin Investig 1993; 71: 49-53.

  9. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D’Errico A, Simon N, Grigioni W, Alberti A, Beaugrand M, Pisi E, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345(8947): 413-5.

  10. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101(7): 1616-22.

  11. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1,124 patients. Liver Int 2007; 27(2): 186-91.

  12. Ramia JM, Villar J, Muffak K, Medina A, Garrote D, Ferrón JA. [Hepatocarcinoma in noncirrhotic liver]. Cir Esp 2006; 80: 111-3.

  13. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl. 1): S35-50.

  14. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005; 19: 25-37.

  15. Tabor E. Pathogenesis of hepatitis B virus-associated hepatocellular carcinoma. Hepatol Res 2007; 37 Suppl 2: S110-4.

  16. Kadokawa Y, Omagari K, Ohba K, Kitamura S, Ohara H, Takeshima F, Mizuta Y, Nanashima A, Yamaguchi H, Kohno S. Hepatocellular carcinoma in a male patient with early stage (stage I) primary biliary cirrhosis. Intern Med 2005; 44: 207-11.

  17. Wakai T, Shirai Y, Tsukada K, Aono T, Kurosaki I, Hatakeyama K. Hepatocellular carcinoma associated with precirrhotic primary biliary cirrhosis successfully treated by a right hepatic lobectomy: report of a case. Surg Today 1996; 26: 723-6.

  18. Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci 2007; 334: 228-30.

  19. Okino H, Satoh T, Watanabe J, Masumoto A, Takeda S. Hepatocellular carcinoma arising from autoimmune hepatitis: report of a case. Surg Today 2007; 37(8): 716-8.

  20. Smalley SR, Moertel CG, Hilton JF, Weiland LH, Weiand HS, Adson MA, Melton LJ 3rd, Batts K. Hepatoma in the noncirrhotic liver. Cancer 1988; 62: 1414-24.

  21. Nakayama M, Kamura T, Kimura M, Seki H, Tsukada K, Sakai K. Quantitative MRI of hepatocellular carcinoma in cirrhotic and noncirrhotic livers. Clin Imaging 1998; 22: 280-3.

  22. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005; 201: 663-70.

  23. Martin RC 2nd, Loehle J, Scoggins CR, McMasters KM. Kentucky hepatoma: epidemiologic variant or same problem in a different region? Arch Surg 2007; 142: 431-6; discussion 436-7.

  24. Kiss A, Lotz G, Kaposi NP, Schaff Z. [Hepatitis viruses and hepatocarcinogenesis]. Orv Hetil 2002; 143: 83-6.

  25. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11(8): 985-94.

  26. Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. Hepatology 1982; 2: 553-6.

  27. Koike K. Pathogenesis of HCV-associated HCC: Dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007; 37 Suppl 2: S115-20.




2020     |     www.medigraphic.com